Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AcSé: Nivolumab in Selected Rare Cancer Types
NCT03012581Phase 2Completed
- Sponsor
- Unicancer
- Start
- Jun 2017
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in non-clear cell renal cell carcinoma (nccRCC), head and neck cancer (HNC), skin cancer and 3 more, sponsored by Unicancer. Primary endpoint: Objective Response Rate at 12 weeks. Started Jun 2017; status: completed.
02
Drugs
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)head and neck cancer (HNC)skin cancermicrosatellite instability-high cancerpenile cancer
Beyond the preview
Go deeper on NCT03012581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03012581.